Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



How Helping Others Lose Weight Could Save You Money

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Do you know someone who needs to lose weight? Helping them do so could end up saving you money over the long run. What's more, even helping a total stranger lose weight could save you money as well. How can this be true? We first need to take a look at Medicare. 

Nearly 1.5% of every dollar you make goes to the federal health care program. If you're self-employed, you kick in twice as much because you must pay the employer's portion also. And if you fit in Obamacare's high income classification, you'll tack on another 0.9%. 

But you're really paying even more for Medicare. Of the $530 billion received by the federal program in 2011, $223 billion came from the general Treasury fund and only around $196 billion derived from payroll taxes. The government actually spent $550 billion -- more than it received. That total amounts to a little over $12,000 spent per enrollee.

As Medicare spending grows, more money will be needed. Guess who's going to pay up? All of us. However, if the spending could somehow be controlled, taxpayers should be able to hang on to more of their hard-earned dollars. That's where a new study comes into play.

Dr. Kenneth Thorpe -- a former Deputy Assistant Secretary for the U.S. Department of Health and Human Services and current chair of the Department of Health Policy and Management at Emory University's Rollins School of Public Health -- led the research team that conducted a study published recently in Health Economics Review. This study found that more than $12,000 per patient could be saved over a 10-year period by helping Medicare beneficiaries lose weight. That comes to as much as $144 billion.

The problem is in actually achieving that weight loss. Bariatric surgery can cost at least $18,000. That wipes out all of the estimated savings. Intensive behavioral therapy, or IBT, for weight loss is much less expensive, but it isn't enough for many obese individuals. Is there another option? Thorpe and his colleagues suggest that combining IBT with new weight-loss drugs could hold the key to helping Medicare beneficiaries lose weight and thereby reducing spending.

Currently, two weight-loss drugs have been approved by the Food and Drug Administration. VIVUS (NASDAQ: VVUS  ) markets Qsymia. Arena Pharmaceuticals (NASDAQ: ARNA  ) stands ready to begin selling Belviq once the Drug Enforcement Administration finalizes scheduling of the obesity drug. Another company, Orexigen Therapeutics (NASDAQ: OREX  ) , hopes to receive approval for Contrave and launch the drug commercially in 2014. The problem for those who think one or more of these drugs could help with lowering Medicare costs is that the program doesn't reimburse patients for taking any of them. Not a dime.

The FDA agreed that Qsymia and Belviq are safe enough for the public. Clinical studies found both drugs to be effective in helping patients lose weight. Even one of the studies that the government used as a basis for its decision to reimburse for IBT concluded that combining weight-loss drugs with behavioral interventions was a good approach. So why doesn't Medicare provide reimbursement for these drugs?

History gives us the answer. Safety problems in the past have marred the image of weight-loss drugs. However, the newer obesity drugs have had to jump through hoops to prove that they are safe to take. Leading companies like Aetna (NYSE: AET  ) and pharmacy benefits manager Express Scripts (NASDAQ: ESRX  ) have opted to cover Qsymia. I expect that they -- and others -- will do the same for Belviq and ultimately for Contrave.

Should Medicare follow suit? Yes. While we should note that Thorpe's study was funded by VIVUS, the approach and reasoning used appears to be solid. With so many potential medical complications arising from obesity, significant savings could be attained by helping Medicare beneficiaries lose weight. Clinical studies show that new weight-loss drugs Qsymia and Belviq work and are reasonably safe. My expectation is that the same will hold true for Contrave.

Be glad if part of your tax dollars that go to Medicare are ultimately used to help others lose weight by taking obesity drugs -- or through any other cost-effective way possible, for that matter. Unless something is done differently, the things that will lose the most weight will be our pocketbooks.

Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2449528, ~/Articles/ArticleHandler.aspx, 9/29/2016 9:40:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,339.24 110.94 0.00%
S&P 500 2,168.55 -2.82 -0.13%
NASD 5,318.55 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
ARNA $1.77 Down -0.04 +0.00%
Arena Pharmaceutic… CAPS Rating: ***
OREX $3.29 Up +0.05 +0.00%
Orexigen Therapeut… CAPS Rating: **
VVUS $1.17 Down -0.03 +0.00%
VIVUS CAPS Rating: **
AET $116.26 Up +0.52 +0.00%
Aetna CAPS Rating: ***
ESRX $70.93 Up +0.14 +0.00%
Express Scripts CAPS Rating: *****